Search

Nerandomilast

[L54126] Compared to pan-PDE4 inhibitors, selective PDE4B inhibitors are associated with a lower potential for gastrointestinal adverse events.[A274581] On December 19, 2025, the U.S.

Nabiximols

The negative allosteric modulatory effects of CBD are therapeutically important as direct agonists are limited by their psychomimetic effects while direct antagonists are limited by their depressant effects … adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy.

Corticorelin

It is made naturally by the hypothalamus (a part of the brain) and can also be made in the laboratory. … Human corticotropin-releasing factor may help reduce symptoms caused by edema (swelling) of the brain. It is a type of neurohormone, also called hCRF.

Rilapladib

Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques.

PN0621

It is being developed by Peptech. … PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis.

Paroxetine

[T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.

Lesopitron

Lesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.

Inecalcitol

Brasofensine

Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.

Alfentanil

Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. … It produces an early peak analgesic effect and fast recovery of consciousness.